Perella Weinberg Partners has added Brian Silver as a new Partner in its New York office. Mr. Silver will work in the firm’s advisory business and will focus on clients in the healthcare sector. He joins Perella’s team of six healthcare sector advisory professionals led by Partners Christopher O’Connor and Philippe McAuliffe in New York, and Managing Director Nick Johnston in London.
Mr. Silver has approximately 20 years of investment banking and corporate legal experience. He was most recently a Managing Director in Morgan Stanley’s Healthcare Investment Banking Group, where he advised a range of biopharmaceutical and pharmaceutical services clients on mergers and acquisitions, initial public offerings, the equity and debt capital markets, and royalty financing. Prior to joining Morgan Stanley in 1998, Mr. Silver was an M&A Associate at Sullivan & Cromwell and an M&A investment banker at Salomon Brothers. Mr. Silver received an AB in Social Studies from Harvard College and a JD from the University of Chicago Law School.
“Attracting high-caliber talent in areas where we believe we can have meaningful impact and where we can provide world-class advice is a primary focus for the firm. Adding Brian to our team illustrates this continued approach and enhances our coverage of the healthcare sector. His broad pharmaceutical and healthcare industry experience complements our existing capabilities and allows us to advise clients across a greater segment of the healthcare sector,” said Peter Weinberg, a Founding Partner and Head of Advisory at Perella Weinberg.
Perella Weinberg Partners provides advisory and asset management services to corporations, institutions and governments. The firm has more than 400 employees and has offices in New York, London, Abu Dhabi, Beijing, Denver, Dubai, and San Francisco (www.pwpartners.com).
“Perella Weinberg Partners is a highly-respected independent advisory firm, with a significant commitment and track record in healthcare investment banking. I am excited to join their experienced team to further expand coverage of the biopharmaceutical and pharmaceutical services sectors,” said Mr. Silver. “Commercial and regulatory changes in the healthcare industry are driving high levels of strategic activity and significant evolution of business models. I look forward to working with my new colleagues to help our clients navigate these challenges.”
© 2013 PEPD • Private Equity’s Leading News Magazine • 7-2-13